ADVFN - Advanced Financial Network.
HOME» NASDAQ » H » HGSI Stock Price » HGSI Stock News

Human Genome Sciences Share News

 Human Genome Sciences (mm) Stock Price
HGSI Stock Price
 Human Genome Sciences (mm) Stock Chart
HGSI Stock Chart
 Human Genome Sciences (mm) Stock News
HGSI Stock News
 Human Genome Sciences (mm) Company Information
HGSI Company Information
 Human Genome Sciences (mm) Stock Trades
HGSI Stock Trades

GlaxoSmithKline To Launch $13/Share Tender Offer For To Buy HGS

LONDON -(Dow Jones)- Research-based pharmaceutical and healthcare company GlaxoSmithKline PLC (GSK) said Wednesday it won't participate in Human Genome Sciences Inc (HGSI) strategic alternatives review process and will instead start a tender offer this week to buy all of the outstanding shares of HGS for $13.00 per share in cash. MAIN FACTS: -GSK's offer represents a premium of 81% to HGS's closing share price of $7.17 on April 18. -GSK values the long relationship it has with HGS and has clearly stated its preference to complete a transaction on a friendly basis in a timely fashion. -GSK remains willing to meet and review its offer with HGS at any time. -GSK shares closed Tuesday at 1407 pence valuing the company at GBP71.83 billion. -By Ian Walker, Dow Jones Newswires; 44-20-7842-9296; ian.walker@dowjones.com

Stock News for Human Genome Sciences (HGSI)
DateTimeHeadline
No Recent News Available

Human Genome Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad